Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr;11(2):83-94.
doi: 10.14740/gr990w. Epub 2018 Apr 7.

Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review

Fotios S Fousekis  1 , Vasileios I Theopistos  1 , Konstantinos H Katsanos  1 , Epameinondas V Tsianos  1 , Dimitrios K Christodoulou  1
Affiliations
Review

Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review

Fotios S Fousekis et al. Gastroenterology Res. 2018 Apr.

Abstract

Liver and biliary track diseases are common extraintestinal manifestations of inflammatory bowel disease (IBD), reported both in Crohn's disease and ulcerative colitis, and may occur at any time during the natural course of the disease. Their etiology is mainly related to pathophysiological changes induced by IBD, and secondary, due to drugs used in IBD. Fatty liver is considered as the most frequent hepatobiliary manifestation in IBD, while primary sclerosing cholangitis (PSC) is the most correlated hepatobiliary disorder and is more prevalent in patients with ulcerative colitis. PSC can cause serious complications from the liver, biliary tree, and gallbladder and can lead to liver failure. Less frequently, IBD-associated hepatobiliary manifestations include cholelithiasis, granulomatous hepatitis, portal vein thrombosis, IgG4-related cholangiopathy, pyogenic liver abscess, hepatic amyloidosis and primary biliary cirrhosis. Most of the drugs used for IBD treatment may cause liver toxicity. Methotrexate and thiopurines carry the higher risk for hepatotoxicity, and in many cases, dose adjustment may normalize the liver biochemical tests. Reactivation of hepatitis B and C virus during immunosuppressive use, especially during use of biological agents, is a major concern, and adequate screening, vaccination and prophylactic treatment is warranted.

Keywords: Extraintestinal manifestations; Hepatitis B; Hepatitis C; Hepatotoxicity; Primary sclerosing cholangitis.

PubMed Disclaimer

Conflict of interest statement

None of the authors has any conflict of interest to report that may be related to this submission.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ott C, Scholmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013;10(10):585–595. doi: 10.1038/nrgastro.2013.117. - DOI - PubMed
    1. Yarur AJ, Czul F, Levy C. Hepatobiliary manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2014;20(9):1655–1667. doi: 10.1097/MIB.0000000000000065. - DOI - PubMed
    1. Mendes FD, Levy C, Enders FB, Loftus EV Jr, Angulo P, Lindor KD. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol. 2007;102(2):344–350. doi: 10.1111/j.1572-0241.2006.00947.x. - DOI - PubMed
    1. Navaneethan U. Hepatobiliary manifestations of ulcerative colitis: an example of gut-liver crosstalk. Gastroenterol Rep (Oxf) 2014;2(3):193–200. doi: 10.1093/gastro/gou036. - DOI - PMC - PubMed
    1. Olsson R, Danielsson A, Jarnerot G, Lindstrom E, Loof L, Rolny P, Ryden BO. et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology. 1991;100(5 Pt 1):1319–1323. doi: 10.1016/0016-5085(91)90784-I. - DOI - PubMed

LinkOut - more resources